Covered recipient · General Payments record
BROOKE N DEWEESE
Physician Assistants & Advanced Practice Nursing Providers Physician Assistant Medical
General Payments · PY2021–2024
$2,050.17
- Reported across 123 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $578.71 | 35 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Acerta Pharma LLC | $161.20 | 3 |
| Amgen Inc. | $150.30 | 18 |
| Novo Nordisk AS | $53.57 | 3 |
| Astellas Pharma US Inc | $43.95 | 2 |
| ABBVIE INC. | $38.11 | 2 |
| Grifols USA, LLC | $36.67 | 2 |
| Lilly USA, LLC | $26.30 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $21.50 | 1 |
| PFIZER INC. | $19.49 | 1 |
| ITI, Inc. | $17.10 | 1 |
| CeQur Corporation | $10.52 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (35)
Sorted by paying entity, then date · as published by CMS
Program year 2024 202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $21.63 | 05/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107017712 | CMS |
| ABBVIE INC. | $16.48 | 06/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107017714 | CMS |
| Amgen Inc. | $6.40 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117540714 | CMS |
| Amgen Inc. | $7.87 | 04/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117540716 | CMS |
| Amgen Inc. | $15.92 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117540718 | CMS |
| Amgen Inc. | $6.38 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117540720 | CMS |
| Amgen Inc. | $6.81 | 06/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117540722 | CMS |
| Amgen Inc. | $6.84 | 07/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117540724 | CMS |
| Amgen Inc. | $2.24 | 08/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117540726 | CMS |
| Amgen Inc. | $19.23 | 08/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117540728 | CMS |
| Amgen Inc. | $6.24 | 09/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117540730 | CMS |
| Amgen Inc. | $10.21 | 09/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115570268 | CMS |
| Amgen Inc. | $6.99 | 09/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117540732 | CMS |
| Amgen Inc. | $2.30 | 10/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117540734 | CMS |
| Amgen Inc. | $7.11 | 10/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117540736 | CMS |
| Amgen Inc. | $9.38 | 10/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117540738 | CMS |
| Amgen Inc. | $8.18 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117540740 | CMS |
| Amgen Inc. | $6.01 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117540742 | CMS |
| Amgen Inc. | $19.06 | 12/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117540744 | CMS |
| Amgen Inc. | $3.13 | 12/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117540746 | CMS |
| Astellas Pharma US Inc | $26.55 | 04/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139497004 | CMS |
| Astellas Pharma US Inc | $17.40 | 12/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139557175 | CMS |
| AstraZeneca Pharmaceuticals LP | $117.64 | 04/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105735599 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.97 | 07/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104603826 | CMS |
| AstraZeneca Pharmaceuticals LP | $23.59 | 09/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104297904 | CMS |
| CeQur Corporation | $10.52 | 05/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1099648891 | CMS |
| Grifols USA, LLC | $16.66 | 05/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124718766 | CMS |
| Grifols USA, LLC | $20.01 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124718768 | CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.10 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143428231 | CMS |
| Lilly USA, LLC | $26.30 | 04/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135554288 | CMS |
| Novo Nordisk Inc | $15.85 | 07/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100401617 | CMS |
| Novo Nordisk Inc | $20.58 | 08/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100236262 | CMS |
| Novo Nordisk Inc | $17.14 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100611446 | CMS |
| PFIZER INC. | $19.49 | 04/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131591204 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $21.50 | 04/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137734372 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.